269 related articles for article (PubMed ID: 37370858)
1. Targeted Therapies and Developing Precision Medicine in Gastric Cancer.
Pihlak R; Fong C; Starling N
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370858
[TBL] [Abstract][Full Text] [Related]
2. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
Karim F; Amin A; Liu M; Vishnuvardhan N; Amin S; Shabbir R; Swed B; Khan U
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627127
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma.
Dhakras P; Uboha N; Horner V; Reinig E; Matkowskyj KA
Transl Gastroenterol Hepatol; 2020; 5():55. PubMed ID: 33073050
[TBL] [Abstract][Full Text] [Related]
4. Updates on breast biomarkers.
Najjar S; Allison KH
Virchows Arch; 2022 Jan; 480(1):163-176. PubMed ID: 35029776
[TBL] [Abstract][Full Text] [Related]
5. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.
Sato Y; Okamoto K; Kawano Y; Kasai A; Kawaguchi T; Sagawa T; Sogabe M; Miyamoto H; Takayama T
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510761
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies in Advanced Gastric Cancer.
Patel TH; Cecchini M
Curr Treat Options Oncol; 2020 Jul; 21(9):70. PubMed ID: 32725377
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
8. Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona N; Gambardella V; Huerta M; Roselló S; Cervantes A
Curr Oncol Rep; 2016 Jul; 18(7):41. PubMed ID: 27215435
[TBL] [Abstract][Full Text] [Related]
9. HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives.
Li W; Zhang X; Du Y; Zhang Y; Lu J; Hu W; Zhao J
Biomark Res; 2022 Sep; 10(1):71. PubMed ID: 36175985
[TBL] [Abstract][Full Text] [Related]
10. New agents on the horizon in gastric cancer.
Lordick F; Shitara K; Janjigian YY
Ann Oncol; 2017 Aug; 28(8):1767-1775. PubMed ID: 28184417
[TBL] [Abstract][Full Text] [Related]
11. Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination.
Rha SY; Chung HC
J Gastric Cancer; 2023 Jan; 23(1):224-249. PubMed ID: 36751001
[TBL] [Abstract][Full Text] [Related]
12. Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy.
Gervaso L; Bottiglieri L; Meneses-Medina MI; Pellicori S; Biffi R; Fumagalli Romario U; De Pascale S; Sala I; Bagnardi V; Barberis M; Cella CA; Fazio N
Clin Transl Oncol; 2023 Nov; 25(11):3287-3295. PubMed ID: 37084152
[TBL] [Abstract][Full Text] [Related]
13. New drug developments in metastatic gastric cancer.
Tan AC; Chan DL; Faisal W; Pavlakis N
Therap Adv Gastroenterol; 2018; 11():1756284818808072. PubMed ID: 30455742
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer.
Kahraman S; Yalcin S
Onco Targets Ther; 2021; 14():4149-4162. PubMed ID: 34285507
[TBL] [Abstract][Full Text] [Related]
15. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
Fong CY; Chau I
Pharmacogenomics; 2021 Jul; 22(11):703-726. PubMed ID: 34120461
[TBL] [Abstract][Full Text] [Related]
16. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
Pous A; Notario L; Hierro C; Layos L; Bugés C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511163
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
18. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma.
Pectasides E
Clin Ther; 2016 Jul; 38(7):1589-99. PubMed ID: 27041412
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J; Gast K; Quiroga D; Lustberg M; Williams N
Expert Rev Anticancer Ther; 2021 Feb; 21(2):135-148. PubMed ID: 33198517
[No Abstract] [Full Text] [Related]
20. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J
Ann Oncol; 2017 Jun; 28(6):1207-1216. PubMed ID: 28327938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
